CSS
DNTH icon

Cubist Systematic Strategies’s Dianthus Therapeutics DNTH Stock Holding History

Cubist Systematic Strategies’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,381
Closed -$808K – 3119
2025
Q2 		$808K Buy
43,381
+21,563
+99% +$405K ﹤0.01% 2053
2025
Q1 		$396K Sell
21,818
-32,948
-60% -$726K ﹤0.01% 2269
2024
Q4 		$1.19M Buy
54,766
+4,518
+9% +$116K 0.01% 1691
2024
Q3 		$1.38M Buy
50,248
+29,272
+140% +$815K 0.01% 1630
2024
Q2 		$543K Sell
20,976
-3,149
-13% -$75.7K ﹤0.01% 2091
2024
Q1 		$724K Buy
+24,125
New +$524K ﹤0.01% 2390
2022
Q3 		– Sell
-667
Closed -$13K – 4485
2022
Q2 		$13K Buy
+667
New +$16.5K ﹤0.01% 4252
2021
Q1 		– Sell
-895
Closed -$112K – 2857
2020
Q4 		$112K Buy
895
+30
+3% +$3.4K ﹤0.01% 2389
2020
Q3 		$94K Buy
+865
New +$102K ﹤0.01% 2295
2018
Q3 		– Sell
-47
Closed -$10K – 1927
2018
Q2 		$10K Buy
+47
New +$10.6K ﹤0.01% 1723

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cubist Systematic Strategies's DNTH Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Dianthus Therapeutics (DNTH) in Q3 2025, closing a stake of 43,381 shares — an estimated $808K sold.

Cubist Systematic Strategies first reported a position in DNTH in Q2 2018 and held it in 10 quarters. The position peaked at $1.38M in Q3 2024. 140 funds tracked by Wall St. Rank hold DNTH as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Dianthus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 43,381 Dianthus Therapeutics shares in Q3 2025, an estimated $808K.
  • Cubist Systematic Strategies first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 10 quarters.
  • Cubist Systematic Strategies's Dianthus Therapeutics position peaked at $1.38M in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.